Medicare expenditures decrease for glaucoma surgery as number of procedures increases
CHICAGO The overall number of glaucoma surgical procedures appears to be increasing, but payments by Medicare for the procedures have been decreasing, according to a report in the July issue of Archives of Ophthalmology , one of the JAMA/Archives journals. Glaucoma is one of the leading cause...Major Firms Eyeing CBMS Development of New Glaucoma Treatment
NEW YORK, MONTREAL and SAN DIEGO, CA, July 7 /PRNewswire-FirstCall/ - Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT), and Ocular Therapeutics Inc. of San Diego California, announced that Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharm...Transcend Medical Raises $35 Million Series B Round Towards Development of Novel Glaucoma Treatment
MENLO PARK, Calif., June 22 /PRNewswire/ -- Transcend Medical, Inc., an ophthalmic device company dedicated to delivering breakthrough advances in the treatment of glaucoma, announced today that it has closed a $35 million Series B round and is continuing the rapid development of its Transcend CyP...Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
EVRY, France, February 27 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, announced the results of its first set of data pertaining to Nova21027, its innovative BAK-free latanoprost formulation for glaucoma. Novagali communicated about "Ocular safety compari...Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
...through treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technol...R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
...company's main product, Rescula(R) eyedrop 0.12%, is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech U...hanism. Concerning Rescula(R) (isopropyl unoprostone) for the treatment of glaucoma and ocular hypertension, R-Tech Ueno concluded a contract with Sucampo Phar...Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
...g rounds from a strong international syndicate of investors. Fovea has built a project portfolio including internal research programs on dry AMD, glaucoma (neuroprotection) and retinal dystrophies as well as clinical programs underway for such indications as allergic conjunctivitis, diabetic macular edem...Molteno3 Glaucoma Drainage Device
Description: Molteno3 Glaucoma Drainage Device incorporates the latest advances from Professor Moltenos glaucoma research. It has been extensively tested since early 2004 and gives even better control of intraocular pressure (IOP) with less risk of hypotony....Humphrey GPA Glaucoma Progression Analysys Software
Description: Only Humphrey GPA software accurately differentiates clinically significant progression of visual field loss from random variability, providing an advanced, proven method to enhance management of glaucoma for your patients. The software applies knowledge acquired from a multi-center clinical tri...Eagle Vision Non-Valved Glaucoma Device
Description: Inquire...Eagle Vision Valved Glaucoma Device
Description: Inquire...DeepLight Glaucoma Treatment System
Description: The SOLX DeepLight Glaucoma Treatment System will provide less invasive, yet highly effective glaucoma treatments through the use of our DeepLight Gold Micro-Shunt (GMS) and DeepLight 790 Titanium Sapphire Laser that help use the eye's natural pressure differential (uveal scleral outflow) to reduce...Genetic sleuth solves glaucoma mystery
Dr. Michael Walter is one good gumshoe. The University of Alberta medical geneticist has cracked the case of WDR36, a gene linked to glaucoma. Glaucoma is a leading cause of blindness in which cells in the optic nerve die, preventing the brain from understanding what patients see. Scientists hav...NJIT applauds students for studies on brain injury, glaucoma and more
A better understanding of brain injury, a way to rejuvenate dead nerve endings and a device allowing patients to monitor their glaucoma at home, number among this years nine winners at NJITs annual provosts student research day. What surprises me every time I walk through this showcase is the s...deCODE discovers cause of major subtype of glaucoma
Reykjavik, Iceland, August 9, 2007 In a paper published today in the journal Science, scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from the National University Hospital in Reykjavik and Uppsala University in Sweden report the discovery of two common single letter variatio...UCF nanoparticle offers promise for treating glaucoma
A unique nanoparticle made in a laboratory at the University of Central Florida is proving promising as a drug delivery device for treating glaucoma, an eye disease that can cause blindness and affects millions of people worldwide. “The nanoparticle can safely get past the blood-brain barrier ma...New Report Just Published: World Solid-State, Fiber, Gas and Dye Lasers Market Report
...ambo(TM)' II-52 Fianium Releases Supercontinuum Lasers II-52 Fianium Launches New Fiber Laser Systems II-53 Solx Receives FDA Approval for glaucoma Treatment Laser II-53 ESI Unveils DPSS Laser for FPD Repair II-53 Zecotek Unveils New Solid-State Laser II-53 IPG Develops Innovative CO2 ...Cell's split personality is a major discovery into neurological diseases
...his week in The Journal of Neuroscience , may lead to more streamlined therapies for a variety of acute and chronic neurological disorders, including glaucoma and retinal artery occlusion. In many neurodegenerative diseases, a main factor that kills neurons is excessive levels of glutamate, the most abun...World Glaucoma Day Set for March 6th
First Annual Observance To Draw Attention To 'The Sneak Thief of Sight' NEW YORK, Jan. 30 /PRNewswire/ -- In an effort to combat one of the main causes of blindness around the globe, the World Glaucoma Association and the World Glaucoma Patient Organization have announced the first annual Worl...WARF licenses patents for new glaucoma drug treatment
Madison, Wis. The Wisconsin Alumni Research Foundation has licensed three patents for developing a new drug that targets the underlying cause of glaucoma, a group of diseases that can lead to blindness. The patents are based on research conducted by Paul Kaufman , a University of Wiscons...R-Tech Ueno Notifies R&D Items
... The item in question is isopropyl unoproston, the effective ingredient of "Rescula(R) eyedrop 0.12%" that is marketed as a therapeutic drug for glaucoma and ocular hypertension. This drug is now being developed by R-Tech Ueno for the indication of retinitis pigmentosa. The drug is introduced to Sucampo...A drug-dispensing contact lens
...100 days. The amounts dispensed were sufficient to kill pathogens in a laboratory assay. Kohane and Ciolino see applications in conditions such as glaucoma and dry-eye which require frequent daily eye drops. They have begun to test the lens in animals and plan to begin human testing as soon as possible. T...